uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancer
Karolinska Univ Hosp, Radiumhemmet, Dept Oncol, Stockholm, Sweden..
Stockholm South Gen Hosp, Dept Oncol, Stockholm, Sweden..
Karolinska Univ Hosp, Radiumhemmet, Dept Oncol, Stockholm, Sweden..
Karolinska Univ Hosp, Radiumhemmet, Dept Oncol, Stockholm, Sweden..
Show others and affiliations
2018 (English)In: Breast Cancer Research and Treatment, ISSN 0167-6806, E-ISSN 1573-7217, Vol. 168, no 2, p. 349-355Article in journal (Refereed) Published
Abstract [en]

Although adjuvant polychemotherapy improves outcomes for early breast cancer, the significant variability in terms of pharmacokinetics results in differences in efficacy and both short and long-term toxicities. Retrospective studies support the use of dose tailoring according to the hematologic nadirs. The SBG 2004-1 trial was a randomized feasibility phase II study which assessed tailored dose-dense epirubicin and cyclophosphamide (EC) followed by docetaxel (T) (group A), the same regimen with fixed doses (group B) and the TAC regimen (group C). Women aged 18-65 years, ECOG PS 0-1 with at least one positive axillary lymph node were randomized 1:1:1. The primary endpoint of the study was the safety and feasibility of the treatment. Toxicity was graded according to CTC-AE version 3.0. The design and short-term toxicity have been previously published. Here, we report safety and efficacy data after 10 years of follow-up. A total of 124 patients were included in the study. After a median follow-up of 10.3 years, the probability for 10-year survival was 78.5, 75.1, and 63.4% and for relapse free survival 64.1, 71.0, and 59.5% for groups A, B, and C, respectively. There were no cases of clinically diagnosed cardiotoxicity or hematologic malignancies. No patient was lost to follow-up. In this randomized phase II trial, tailored dose adjuvant chemotherapy was feasible, without an increased risk for long-term adverse events after a median follow-up of 10 years.

Place, publisher, year, edition, pages
SPRINGER , 2018. Vol. 168, no 2, p. 349-355
Keywords [en]
Adjuvant chemotherapy, Breast cancer, Dose-dense, Randomized, Tailored dose
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:uu:diva-350272DOI: 10.1007/s10549-017-4599-4ISI: 000426778200006PubMedID: 29190004OAI: oai:DiVA.org:uu-350272DiVA, id: diva2:1205402
Funder
Swedish Cancer SocietyKing Gustaf V Jubilee FundThe Karolinska Institutet's Research FoundationSwedish Research CouncilStockholm County CouncilAvailable from: 2018-05-14 Created: 2018-05-14 Last updated: 2018-05-14Bibliographically approved

Open Access in DiVA

fulltext(1023 kB)11 downloads
File information
File name FULLTEXT01.pdfFile size 1023 kBChecksum SHA-512
12436d13cb057b2b6fd685079227df6b4c5c08286678482fe658caa3136c4047d0583e4ebbbc0b1c9a683bf301599986b0ad07e2cb091801907ee82bc45cbc0d
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Authority records BETA

Lindman, Henrik

Search in DiVA

By author/editor
Lindman, Henrik
By organisation
Experimental and Clinical Oncology
In the same journal
Breast Cancer Research and Treatment
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar
Total: 11 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 49 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf